ATE392435T1 - Ostertagia-impfstoff - Google Patents

Ostertagia-impfstoff

Info

Publication number
ATE392435T1
ATE392435T1 AT03750540T AT03750540T ATE392435T1 AT E392435 T1 ATE392435 T1 AT E392435T1 AT 03750540 T AT03750540 T AT 03750540T AT 03750540 T AT03750540 T AT 03750540T AT E392435 T1 ATE392435 T1 AT E392435T1
Authority
AT
Austria
Prior art keywords
tagia
easter
vaccine
tagia vaccine
easter tagia
Prior art date
Application number
AT03750540T
Other languages
English (en)
Inventor
Peter Geldhof
Isabel Vercauteren
Edwin Claerebout
Jozef Vercruysse
Maere Veerle De
Original Assignee
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Gent filed Critical Univ Gent
Application granted granted Critical
Publication of ATE392435T1 publication Critical patent/ATE392435T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03750540T 2002-09-13 2003-09-11 Ostertagia-impfstoff ATE392435T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/243,319 US20040052817A1 (en) 2002-09-13 2002-09-13 Ostertagia vaccine

Publications (1)

Publication Number Publication Date
ATE392435T1 true ATE392435T1 (de) 2008-05-15

Family

ID=31991608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750540T ATE392435T1 (de) 2002-09-13 2003-09-11 Ostertagia-impfstoff

Country Status (11)

Country Link
US (4) US20040052817A1 (de)
EP (1) EP1539820B1 (de)
AR (1) AR041243A1 (de)
AT (1) ATE392435T1 (de)
AU (1) AU2003270190B2 (de)
BR (2) BRPI0314258B1 (de)
CA (1) CA2498249C (de)
DE (1) DE60320425T2 (de)
ES (1) ES2304526T3 (de)
NZ (1) NZ542733A (de)
WO (1) WO2004024769A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052817A1 (en) * 2002-09-13 2004-03-18 Peter Geldhof Ostertagia vaccine
CA2498055A1 (en) * 2002-09-13 2004-03-25 Ovita Limited Aspartyl protease inhibitor as a nematode allergen
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB894603A (en) * 1959-09-02 1962-04-26 Allen & Hanburys Ltd Improvements in or relating to vaccines
CN1132514A (zh) 1993-09-28 1996-10-02 墨尔本大学 针对寄生虫的保护性抗原
US5753787A (en) * 1995-04-10 1998-05-19 Yale University Nucleic acids encoding ancylostoma secreted protein
US5759782A (en) * 1995-06-07 1998-06-02 The United States Of America Cellular apoptosis susceptibility protein (CSP) and antisense CSP
US6017757A (en) * 1997-02-20 2000-01-25 Mississippi State University Isolated viable nematode intestinal cells
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US20040052817A1 (en) * 2002-09-13 2004-03-18 Peter Geldhof Ostertagia vaccine

Also Published As

Publication number Publication date
US7718179B2 (en) 2010-05-18
BR0314258A (pt) 2005-07-26
US8227584B2 (en) 2012-07-24
ES2304526T3 (es) 2008-10-16
NZ542733A (en) 2007-06-29
AU2003270190A1 (en) 2004-04-30
US20040052817A1 (en) 2004-03-18
US20100209446A1 (en) 2010-08-19
EP1539820A2 (de) 2005-06-15
EP1539820B1 (de) 2008-04-16
US20050271683A1 (en) 2005-12-08
AR041243A1 (es) 2005-05-11
AU2003270190B2 (en) 2008-09-04
DE60320425T2 (de) 2008-07-31
WO2004024769A2 (en) 2004-03-25
DE60320425D1 (de) 2008-05-29
US7264812B2 (en) 2007-09-04
US20090028892A1 (en) 2009-01-29
CA2498249C (en) 2016-09-06
BRPI0314258B1 (pt) 2019-07-09
CA2498249A1 (en) 2004-03-25
WO2004024769A3 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
NO20054608D0 (no) Influensavirusvaksine
IS7547A (is) Ónæmisvaldandi samsetningar
DE602004028754D1 (de) -substituierter diarylaminanaloga
NO20050132D0 (no) Vaksinesammensetning
DK1427444T3 (da) West-nil-vaccine
IS7831A (is) Bóluefni
NO20033882D0 (no) Vaksine
GB0225788D0 (en) Vaccine
DE60328408D1 (de) Impfstoff
GB0228715D0 (en) Vaccine
GB0209878D0 (en) Vaccine
NO20051561D0 (no) Vaksine
IS2922B (is) Bóluefni
GB0305794D0 (en) Vaccine
GB0305793D0 (en) Vaccine
ATE392435T1 (de) Ostertagia-impfstoff
GB0206595D0 (en) Vaccine
IL156434A0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0226179D0 (en) Vaccine
UA6719S (uk) Ваза
GB0216582D0 (en) Vaccine
GB0213364D0 (en) Vaccine
GB0220212D0 (en) Vaccine
GB0220211D0 (en) Vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties